For the year ending 2025-12-31, CHRS made $42,172K in revenue. $168,024K in net income. Net profit margin of 398.43%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Net revenue | 42,172 | |||
| Cost of goods sold | 13,814 | |||
| Research and development | 108,888 | |||
| Selling, general and administrative | 100,604 | |||
| Total costs and expenses | 223,306 | |||
| Loss from operations | -181,134 | |||
| Interest expense | 9,001 | |||
| Loss on debt extinguishment | 0 | |||
| Other income (expense), net | 7,011 | |||
| Loss from continuing operations before income taxes | -183,124 | |||
| Net loss from continuing operations | -183,124 | |||
| Net revenue | 76,613 | |||
| Cost of goods sold | 26,755 | |||
| Research and development | 521 | |||
| Selling, general and administrative | 11,096 | |||
| Total costs and expenses | 38,372 | |||
| Income from operations | 38,241 | |||
| Interest expense | 3,484 | |||
| Gain on sale transactions, net | 338,315 | |||
| Loss on debt extinguishment | -10,286 | |||
| Other income (expense), net | -11,638 | |||
| Net income from discontinued operations before income taxes | 351,148 | |||
| Net income from discontinued operations, net of tax (note 6) | 351,148 | |||
| Net income | 168,024 | |||
| Basic EPS | 1.43 | |||
| Diluted EPS | 1.43 | |||
| Basic Average Shares | 117,143,457 | |||
| Diluted Average Shares | 117,143,457 | |||
Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. (CHRS)